A PAD-T cell targeting acute myeloid leukemia cells, its preparation method and application
By coating the surface of T cells with polylysine and sodium alginate layer by layer and combining them with DNA aptamers, PAD-T cells targeting CD33 were prepared. This solved the problems of lack of targeting in CAR-T cell therapy for AML and the risk of GVHD after DLI treatment, achieving highly efficient killing of AML cells and alleviating GVHD.
Patent Information
- Application Number
- CN202510188410.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2025-02-20
- Publication Date
- 2026-11-10
- Estimated Expiration
- 2045-02-20
AI Technical Summary
Existing CAR-T cell therapy for acute myeloid leukemia (AML) lacks targeting, and there is a risk of GVHD when relapse occurs after donor lymphocyte infusion (DLI) therapy. Current technologies are insufficient to improve killing ability while reducing the incidence of GVHD.
T cells were coated with poly-L-lysine and sodium alginate, and DNA aptamers were attached to their surface using rolling circle amplification technology to form PAD-T cells targeting CD33. The targeting of DNA aptamers was used to kill the cells and reduce the risk of GVHD.
It achieves specific targeted killing of AML cells, reduces the incidence of GVHD, improves treatment efficacy, and ensures the vitality and proliferation capacity of T cells.
Smart Images

Figure CN120204423B_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biomedical technology, specifically relating to a PAD-T cell that targets acute myeloid leukemia cells, its preparation method, and its application. Background Technology
[0002] Cell therapy is a new disease treatment technology that has emerged in recent years. It refers to the use of the characteristics of certain cells with specific functions. The cells are obtained through bioengineering methods and / or produced through in vitro expansion, special culture and other treatments. These cells are then reinfused into the body to achieve the purpose of treating diseases.
[0003] Currently, CAR-T cells have achieved good results in the treatment of B-lymphoblastic leukemia, but due to the lack of specific target antigens, CAR-T therapy has not achieved good results in the treatment of acute myeloid leukemia (AML).
[0004] Allogeneic hematopoietic stem cell transplantation (HSCT) is currently the main clinical method for radical treatment of hematologic malignancies, especially for refractory / relapsed AML that has not responded well to chemotherapy or targeted therapy. Relapse is one of the main reasons for HSCT failure in treating hematologic malignancies. Post-transplant relapse has a poor prognosis, and there are no effective treatments. Traditional treatments include discontinuation of immunosuppressants, chemotherapy and radiotherapy, and re-transplantation. The development of donor lymphocyte infusion (DLI) has brought hope for alleviating post-transplant relapse. In recent years, although DLI treatment has greatly improved post-transplant relapse, the safety of complications such as infusion-associated graft-versus-host disease (GVHD) remains a challenge and affects the efficacy of DLI.
[0005] Improving the ability of donor lymphocytes to kill AML cells and reducing the incidence of GVHD in DLI treatment is the bottleneck in clinical DLI treatment for post-transplant relapse.
[0006] A related patent (ZL 2021 1 1025332.1) discloses a GA-T cell and its preparation method, as well as its application in leukemia and anti-GVHD. The GA-T cells are prepared by coating donor lymphocytes with cationic aminated gelatin and anionic sodium alginate through layer-by-layer self-assembly, and are used to prevent GVHD in allogeneic hematopoietic stem cell transplantation. However, developing a new technology that can both prevent GVHD and target and kill tumors remains a bottleneck problem that needs to be overcome in clinical practice. Summary of the Invention
[0007] To address the aforementioned technical problems, one objective of this invention is to provide a PAD-T cell that targets acute myeloid leukemia cells.
[0008] The technical solution adopted in this invention is as follows: A PAD-T cell targeting acute myeloid leukemia cells includes T cells, a capsule encapsulating the T cells, and a DNA aptamer connected to the capsule. The capsule is composed of alternating layers of a first polylysine layer, a first sodium alginate layer, and a second polylysine layer. The DNA aptamer layer is an S30-T1 DNA aptamer with the sequence shown in SEQ ID NO.1.
[0009] The DNA aptamer is a long DNA chain containing n S30-T1 DNA aptamer units. Preferably, n is 1000-5000; more specifically, 2000-4000, 2500-3500.
[0010] The second objective of this invention is to provide a method for preparing PAD-T cells targeting acute myeloid leukemia cells as described above, comprising the following steps: S1. Process the selected qualified T cells into a single-cell suspension; S2. Add polylysine solution to the cell suspension and incubate to allow polylysine to adsorb onto the surface of the T cells, forming a first polylysine layer; S3. Add sodium alginate solution and incubate to allow sodium alginate to coat the outside of the first polylysine layer, forming the first sodium alginate layer; S4. Repeat step S2 to form the second polylysine layer; S5. Add the DNA rolling circle amplification system solution to the cell suspension from step S4, incubate, and obtain the desired PAD-T cells; the DNA rolling circle amplification system solution includes DNA aptamer primer strands, DNA aptamer template strands, ligase, DNA polymerase, and deoxyribonucleoside triphosphates, the DNA aptamer primer strand sequence is shown in SEQ ID NO.2, and the DNA aptamer template strand sequence is shown in SEQ ID NO.3.
[0011] Preferably, the single-use volume of the poly-L-lysine solution is 1 mL / 10 5-7 T cells, preferably 1 mL / 10 6 For each T cell, the single-dose sodium alginate solution is 1 mL / 10. 5-7 T cells, preferably 1 mL / 10 6The volume ratio of the material solution to the T cell suspension is 0.5-1.5:0.5-1.5, preferably 1:1, and the incubation time is 2-60 min.
[0012] Preferably, the specific steps for DNA rolling circle amplification are as follows: S51. Mix DNA aptamer primer strands, DNA aptamer template strands, and ligase buffer, and anneal for PCR. S52. Add T4 ligase and incubate; S53. Add Φ29 DNA polymerase, deoxyribonucleoside triphosphate, bovine serum albumin, and Φ29 DNA polymerase reaction solution, mix with the cell suspension from step S4, incubate, and obtain the desired PAD-T cells.
[0013] In a specific embodiment, the amount of DNA aptamer template strand added is 0.4-0.8 μM, for example 0.6 μM, and the amount of DNA aptamer primer strand added is 1.0-1.4 μM, for example 1.2 μM. Then, 10× ligase buffer is added, and the volume is made up with deionized water. Specifically, the final reaction volume based on DNA rolling circle amplification is set at 100 μl.
[0014] Preferably, the PCR program is as follows: annealing at 95℃ for 2 min, 65℃ for 30 min, 50℃ for 30 min, 37℃ for 30 min, and 22℃ for 30 min. After annealing, add T4 ligase at a concentration of 10 U / μL. After incubation for 3 hours, add Φ29 DNA polymerase at a concentration of 2 U / μL and deoxyribonucleoside triphosphate at a concentration of 2 mM / μL. Add deionized water to bring the volume to 100 μL.
[0015] The ratio of the total volume of the rolling circle amplification reaction system to the volume of the cell suspension is 1:5-15, preferably 1:9-11, such as 1:10.
[0016] Preferably, the incubation time in step S52 is 3 hours, and the incubation time in step S53 is 1 to 2 hours.
[0017] A third objective of this invention is to provide the application of PAD-T cells targeting acute myeloid leukemia cells as described above in the preparation of drugs to alleviate infusion-related graft-versus-host disease.
[0018] The fourth objective of this invention is to provide the application of the PAD-T cells targeting acute myeloid leukemia cells as described above in the preparation of a drug for treating relapse after hematopoietic stem cell transplantation.
[0019] The beneficial effects of this invention are as follows: using biopolymer materials poly-L-lysine and sodium alginate, along with nucleic acid material DNA aptamers, a nanofilm is assembled by layering T cells through electrostatic adsorption. The biomaterial layer and the DNA aptamer layer respectively play the roles of immune isolation and targeting acute myeloid leukemia cells. This invention can coat T cells into single cells, thereby regulating proliferation, differentiation, and intercellular interactions.
[0020] More specifically, CD33 is a myeloid cell differentiation antigen, highly expressed on proto-AML cells in most patients and possibly on leukemia stem cells in some patients. Therefore, it has been used as a therapeutic target in cell therapy for many years. A review published in *Blood* mentions that there are studies on CD33-based CAR-T cells targeting AML cells, but these have safety concerns regarding myelotoxicity. This invention creatively inserts a CD33-targeting nucleic acid aptamer onto the coating T cells and synthesizes ultralong nucleotide single chains containing the aptamer using rolling circle amplification technology. The nucleotide single chains are adsorbed onto the T cell coating layer through electrostatic interactions, forming a four-layer nanofilm of biomaterial and nucleic acid material, thus improving safety. This application ensures the targeting specificity of the DNA aptamer to CD33, which is highly expressed in AML. PAD-T cells can target and kill AML cells through the outermost DNA aptamer layer without affecting normal cells.
[0021] The method of this invention ensures optimal viability and coating efficiency of PAD-T cells. After being coated with four layers (poly-L-lysine (PLL) – alginate – poly-L-lysine – S30-T1 DNA aptamer), PAD-T cells form a relatively smooth capsule. The outermost DNA aptamer layer and poly-L-lysine layer of PAD-T cells gradually degrade within 96 hours. Furthermore, PAD-T cells exhibit electrical potential and proliferative capacity similar to immune cells. In addition, PAD-T cells possess greater mechanical rigidity than conventional T cells, maintaining good cell viability even after five repeated centrifugal cycles at 3000-5000 rpm and under conditions of pH ≤ 6.5 or ≥ 8.
[0022] According to the present invention, peripheral blood mononuclear cells from healthy donors can be prepared on a large scale using nanocoating technology for the treatment of relapse after allogeneic tumor transplantation. In cases of relapse after hematopoietic stem cell transplantation, the immune isolation concept described in this application, combined with the biomaterial-nucleic acid material-coated immune cell technology, optimizes the clinical method of timely relapse suppression through donor lymphocyte infusion. This not only improves the tumor-killing effect in relapse cases but also significantly alleviates the occurrence of GVHD, demonstrating extremely high clinical application potential. Attached Figure Description
[0023] Figure 1 This is a flow cytometry plot showing the coating efficiency of the DNA aptamer layer in this application.
[0024] Figure 2 This is a flow cytometry diagram of the DNA aptamer targeting AML cells in this application.
[0025] Figure 3 This is a laser confocal image of the DNA aptamer targeting AML cells in this application.
[0026] Figure 4 This is a layer diagram of the coating material for PAD-T fluorescence observation in this application.
[0027] Figure 5 This is a PAD-T cell potential detection diagram from this application.
[0028] Figure 6 This is a flow cytometry plot of PAD-T proliferation capacity detected by the CFSE method in this application.
[0029] Figure 7 This is a diagram showing the resistance of PAD-T to physical stress and external environment for testing purposes in this application.
[0030] Figure 8 This is a graph showing the release level of PAD-T cytokines detected by enzyme-linked immunosorbent assay (ELISA) in this application.
[0031] Figure 9 Flow cytometry plot of PAD-T targeting and killing AML cells.
[0032] Figure 10 Flow cytometry was used to detect PAD-T killing of AML cells using the Annexin V-PI apoptosis kit.
[0033] Figure 11 This is a schematic diagram of the activation marker flow of PAD-T cells co-cultured with mouse macrophages. Detailed Implementation
[0034] To facilitate understanding, the technical solution of the present invention will be described in more detail below with reference to the embodiments.
[0035] In this application, P stands for poly-L-lysine, A stands for sodium alginate, and D stands for DNA aptamer.
[0036] Unless otherwise specified, all raw materials, reagents, instruments and equipment used in this article can be purchased from the market or prepared by existing methods.
[0037] Example 1: Preparation of PDA-T cells 1. Extraction and expansion of mouse T cells, including the following steps: S1. Preparation of splenic lymphocytes: Under aseptic conditions, spleens of normal C57BL / 6 mice were collected, and 4-5 mL of lymphocyte separation medium was placed in a 35 mm sterile culture dish. The mouse spleen was placed in a sterile culture dish and gently ground and filtered through a 200-mesh cell sieve using a 5 mL syringe needle core. The filtrate containing the suspended spleen cells was immediately transferred to a 15 mL centrifuge tube and covered with 200-500 µL of RPMI medium (keeping the liquid surface clearly demarcated). Centrifuged at 800 g for 30 min at room temperature. The lymphocyte layer was aspirated, and 10 mL of RPMI medium was added, followed by inverted washing. The cells were collected by centrifugation at 250 g for 10 min at room temperature. The cells were resuspended in serum-free RPMI and counted to the desired cell count; trypan blue staining was performed to count the number of viable cells.
[0038] S2. Magnetic bead sorting: Splenic lymphocytes obtained in S1 are sorted using magnetic beads (per 10). 7 Each cell was resuspended in 100 µL LMACS buffer (magnetic beads for cell sorting) and incubated with CD3 T cell-negative magnetic beads for 15 minutes. After washing (300 g / 10 min), the cells were resuspended in separation buffer. The labeled cell suspension was added to the sorting column and eluted three times with buffer. The labeled cells were separated, and the unlabeled T cells were collected. Primary T cells were obtained.
[0039] S3. In vitro expansion and culture of mouse T cells: Primary T cells obtained in S2 were cultured at a concentration of 1×10⁻⁶ cells / cells. 6 mL of cells were seeded into 10 (v / v)% RPMI medium (2 mM L-glutamine, 10% fetal bovine serum, and 100 U / mL penicillin / streptomycin). Mouse T-cell activator Con A (1 mg / mL) was added. 30 U / mL rIL-2 was added, and the cells were cultured in a 37°C CO2 incubator. Cell size and morphology were observed. When the cell density exceeded 2.5 × 10⁻⁶ cells / mL... 6 When the cell / mL or culture medium turns yellow, aliquot the culture medium into a medium containing 30 U / mL rIL-2, restoring the density to 0.5-1 × 10⁻⁶ cells / mL. 6 Cells / mL. Obtain the T cell suspension from expansion culture.
[0040] 2. Poly-L-lysine and sodium alginate triple coating T cells Different concentrations of poly-L-lysine solutions and 0.25 w / v% sodium alginate solutions were prepared at room temperature, and the pH was adjusted to 7.3-7.5. The different concentrations of poly-L-lysine solutions are shown in Table 1 below. The physiological saline used for preparation was 0.9 wt% physiological saline.
[0041] Table 1. Poly-L-lysine solutions of different concentrations
[0042] The prepared T cell suspension was washed with DuPont phosphate buffer to remove residual protein. It was then centrifuged with DuPont phosphate buffer (1500 rpm, 5 min), counted, and resuspended to a concentration of 1 × 10⁻⁶ cells / mL. 6 Take 1 mL of a single-cell suspension (cells / mL) and add it to a 6-well plate. Then add any concentration of poly-L-lysine solution from Table 1, mix gently, and gently blow repeatedly to ensure uniform dispersion. Then place the plate in a constant temperature shaker incubator and shake to mix (500 rpm). Incubate the plate, mixing every 2 minutes to allow the positively charged poly-L-lysine in the poly-L-lysine solution to adsorb onto the negatively charged cell surface, thus completing the first layer of poly-L-lysine coating.
[0043] Cells were transferred to 15 mL centrifuge tubes and centrifuged at 1500 rpm for 5 min. After washing away excess poly-L-lysine solution components, the supernatant was removed, and the cells were washed twice with 5 mL of DuPont phosphate buffer to remove unadsorbed poly-L-lysine. Then, 1 mL of 0.25 w / v sodium alginate solution was added, and the mixture was gently stirred. The mixture was repeatedly blown gently to ensure uniform dispersion. The cells were then incubated in a constant temperature shaker incubator at 500 rpm for 15 min, with the mixture stirred every 3 min to allow the negatively charged sodium alginate to adsorb onto the positively charged poly-lysine surface, thus obtaining the second sodium alginate coating layer.
[0044] After washing and centrifuging the cells, the poly-L-lysine coating step was repeated to complete the third poly-L-lysine coating layer. Table 2 shows the coating efficiency of poly-L-lysine layers at different concentrations and incubation times.
[0045] Table 2. Coating effect of different incubation times and concentrations (unit: %)
[0046]
[0047] Notes: 1. Coating effect is defined as achieving an effective single-cell coating rate (%); 2. “―” indicates significant aggregation, and the effective coating rate could not be calculated.
[0048] Single cells coated with poly-L-lysine were incubated for different times (10 min, 20 min, 30 min, 40 min) with poly-L-lysine solutions of different concentrations (0.001%, 0.01%, 0.1%). From the perspective of coating efficiency, the 0.01% poly-L-lysine solution incubated for 10 min achieved a higher coating efficiency, close to 90%. Therefore, incubation with 0.01 g / 100 ml poly-L-lysine solution for 10 min is preferred for preparing the first and third poly-L-lysine layers.
[0049] 3. T cells coated with S30-T1 DNA aptamer based on rolling circle amplification 3.1 Preparation of S30-T1 DNA aptamers Preparation of S30-T1 DNA aptamer reaction system based on rolling circle amplification: The S30-T1 DNA aptamer sequence is as follows: TTATAGGGGCTGGACAAAATTCTACCCAGCCTTTTCTGA (SEQ ID NO. 1).
[0050] The DNA template strand and primer strand sequences containing the S30-T1 DNA aptamer are as follows: S30-T1 primer chain: ACAAAATTCTACCCAGCCTTGCTGCTGC (SEQ ID NO.2); S30-T1 circular DNA template strand: 5'-P: GAATTTTGTCCAGCCCCTATAATGCTGCTGCCACGTATCACCAGGCCGCAGCAGCATCAGAAAAGGCTGGGTA-3' (SEQ ID NO. 3).
[0051] These two strands were prepared by DNA rolling circle amplification reaction to create a hydrogel containing the S30-T1 DNA aptamer.
[0052] First, prepare a 50 μL reaction system using T4 ligase buffer: Add the above-mentioned 0.6 μM phosphorylated S30-T1 circular DNA single-stranded template and 1.2 μM S30-T1 primer strand to the reaction system, then add 5 μL of 10× ligase buffer, and make up the volume to 50 μL with water. After mixing the above system, anneal it according to the following conditions: 95℃ / 2 min - 65℃ / 30 min - 50℃ / 30 min - 37℃ / 30 min - 22℃ / 30 min. After annealing, add 0.5 μL of T4 ligase to the above system, mix well, and let it stand at room temperature for 3 h to ligate the 5' and 3' ends of the phosphorylated linear template. After adding T4 ligase, the molecular weight of the obtained product increased significantly, indicating that the 5' and 3' ends of the linear template were successfully ligated.
[0053] Add 10 μL of Phi 29 DNA polymerase, 2 μL of deoxyribonucleoside triphosphate, and 0.5 μL of bovine serum albumin solution to the aforementioned DNA template and primer reaction system ligated with T4 ligase. Then add 10 μL of 10×Phi 29 DNA polymerase reaction buffer, and then add the mixture to a centrifuge tube containing 100 μL of the prepared T cells coated with three layers of biological material. Incubate the above reaction system at 37°C for 30 min, 1 h, and 2 h, respectively. After the reaction, centrifuge and wash to terminate the rolling circle amplification reaction, completing the coating process and obtaining poly-L-lysine-sodium alginate-poly-L-lysine-S30-T1 DNA aptamer-coated T cells, i.e., PAD-T cells.
[0054] Example 2: Flow cytometry detection of the coating efficiency of aptamer layers at different rolling circle amplification reaction times (S30-T1). Fluorescein isothiocyanate (FITC) was added before rolling circle amplification to attach a FITC fluorescent tag to the synthesized DNA aptamers, and PAD-T cells were prepared following the steps in Example 1. Flow cytometry was used to detect the fluorescently labeled DNA aptamer layer on PAD-T cells at a wavelength of 488 nm, and the coating efficiency of the DNA aptamer layer was analyzed. The results are shown in Table 3. Figure 1 As shown.
[0055] Table 3 and Figure 1 The results showed that, under different rolling circle amplification reaction times (30 min, 1 h, 2 h), the coating of S30-T1 DNA aptamer layers showed that the coating rate obtained by rolling circle amplification reaction at 1 h was higher, with a coating efficiency of over 80%. Figure 1 The flow cytometry peak plots also show the above results.
[0056] Table 3. Coating effect of different rolling circle amplification reaction times (unit: %)
[0057] Example 3: Flow cytometry detection of the targeting of S30-T1 aptamer to AML cells DNA aptamers were prepared according to the steps in Example 1, and FITC was added before rolling circle amplification to give the synthesized DNA aptamers a FITC fluorescent tag. The fluorescently labeled DNA aptamers were added to 1×10⁻⁶... 6 After incubating AML cells or bone marrow cells at 37°C for 24 hours, the cells were collected, washed with PBS, centrifuged and resuspended. Flow cytometry was then used to detect fluorescently labeled DNA aptamers in the AML cells or bone marrow cells at a wavelength of 488 nm, thereby analyzing the targeting of the S30-T1 DNA aptamer to AML cells.
[0058] Figure 2The results showed that the flow cytometry peaks in the AML cell (Molm-13 and WEHI-3B) groups shifted to the right, indicating that the fluorescent S30-T1 DNA aptamer successfully targeted AML cells. However, the flow cytometry peaks in the bone marrow cell group did not shift significantly to the right, indicating that the S30-T1 DNA aptamer has a specific targeting effect on AML cells.
[0059] Example 4: Laser confocal microscopy detection of the targeting of S30-T1 aptamer to AML cells Collect AML cells or bone marrow cells co-incubated in Example 3, fix them with 2.5% glutaraldehyde for 10 minutes, then incubate with DAPI (4',6-diamidinyl-2-phenylindole) for 15 minutes for cell staining. After washing with phosphate buffer, centrifuging and resuspending, fluorescence expression was detected by laser confocal microscopy at wavelengths of 405 nm and 488 nm.
[0060] Figure 3 The results showed that the S30-T1 DNA aptamer had a high targeting ability for AML cells, but did not target normal bone marrow cells.
[0061] Example 5: Fluorescence microscopy detection of poly-L-lysine and DNA aptamer-coated PAD-T cells Referring to Example 1, PAD-T cells were prepared using CY5-labeled poly-L-lysine and FITC-labeled DNA aptamers. After centrifugation, the cells were washed with washing buffer (50 mL phosphate buffer + 50 μL Tween) and counted. Approximately 1 × 10⁻⁶ cells were aspirated. 6 Centrifuge PAD-T cells, discard the supernatant, add fixative and fix at room temperature for 15 min. Centrifuge, wash, and discard the supernatant. Add 100 µL of 4',6-diamidinyl-2-phenylindole dihydrochloride (DAPI) staining solution and incubate at room temperature in the dark for 30 min. Wash with washing buffer (500 µL / tube); resuspend and centrifuge, discard the supernatant, leaving 20-30 µL of supernatant per tube. Mix the cells thoroughly, drop the mixture onto a glass slide, spread evenly, and air dry. Add a small drop of anti-quenching mounting medium, carefully remove the coverslip, cell-side down, and gently tap it onto the mounting medium. Observe the surface fluorescence of the cells under a laser confocal microscope (excitation wavelengths 358 nm, 488 nm, and 647 nm). See the results of the laser confocal microscope observation. Figure 5 .
[0062] Figure 4 The results showed that the coated PAD-T cells exhibited fluorescence of poly-L-lysine and DNA aptamers on their surface.
[0063] Example 6: Detection of PAD-T cell potentials PAD-T cells were prepared according to Example 1. Cell samples were taken before coating and after each coating layer: cells (Control), cells—poly-L-lysine (1 st PLL), cell-poly-L-lysine-sodium alginate (2 nd ALG), cell-poly-L-lysine-sodium alginate-poly-L-lysine (3 rd PLL), Cell-poly-L-lysine-sodium alginate-poly-L-lysine-S30-T1 DNA aptamer (4 th S30-T1). The surface potential change of PAD-T during the entire coating process was measured using a Malvern nanoparticle size potentiometer. The results are shown in […]. Figure 4 .
[0064] from Figure 5 It can be seen that after four layers of coating, the surface potential of PAD-T cells did not change significantly compared with that before coating (i.e., normal T cells).
[0065] Example 7: CFSE detection of PAD-T proliferation capacity PAD-T cells were prepared according to Example 1. PAD-T cells or conventional uncoated T cells were resuspended in staining working solution to a cell concentration of approximately 10. 7 / mL. Incubate at 37°C for 20 minutes, centrifuge, discard the supernatant, wash cells 1-2 times with PBS, add 10 (V / V)% RPMI medium, and seed cells in 24-well plates (1×10⁶ cells / mL). 6 Cells were cultured at 37°C for 48 hours after incubation with mouse T cell activator ConA (1 mg / mL) and 30 U / mL rIL-2 in a well. Cells were then collected, incubated with Anti-CD3-PE for 30 min, labeled, centrifuged, washed, and the expression of CD3 and CFSE was detected by flow cytometry (cells from the first 0 h of culture were collected, and CD3-labeled cells were used as a blank control). Results are shown below. Figure 5 .
[0066] Figure 6 The results showed that after stimulation with the stimulant, CFSE analysis revealed no significant difference in the proliferation capacity of CD3+PAD-T cells compared to conventional CD3+ T cells.
[0067] Example 8: Testing the physical stress and resistance to external environment of PAD-T cells PAD-T cells were prepared according to Example 1. PAD-T cells coated or conventional uncoated T cells were collected and added to 1.5 mL EP tubes (approximately 1 × 10⁻⁶ cells). 6Samples were treated with different physical stresses generated by centrifugation at different speeds (1000 rpm, 1500 rpm, 2000 rpm, 3000 rpm, 4000 rpm, 5000 rpm) five times. The cells were then resuspended in 10% RPMI medium and seeded into 96-well plates (10 µL / well). The plates were incubated at 37°C for 12 h, and cell viability was assessed using the CCK-8 assay. Results are shown below. Figure 6 Figure A in the middle.
[0068] Collect PAD-T cells or regular uncoated T cells and add them to a 1.5 mL EP tube (approximately 1 × 10⁻⁶ cells). 6 Cells were resuspended in 10 (v / v)% RPMI medium, and the pH of the solution was adjusted to 5.5, 6.5, 7.5, 8, and 9 to simulate different external environments. Cells were then seeded into 96-well plates (10 µL / well) and cultured at 37°C for 12 h. Cell viability was assessed using the CCK-8 assay. Results are shown below. Figure 6 Figure B in the middle.
[0069] Figure 7 The results showed that treating conventional T cells and PAD-T cells with different physical stresses generated by centrifugation speeds (1000 rpm, 1500 rpm, 2000 rpm, 3000 rpm, 4000 rpm, 5000 rpm) for 5 minutes each time, repeated 5 times, and measuring cell viability using the CCK-8 assay, revealed that PAD-T cells, compared to conventional T cells, possessed a certain degree of mechanical strength and significantly reduced the physical damage caused by centrifugation at 2000-5000 rpm. *p<0.05, **p<0.01 (±s, n=5). Simulating different external environments with different solution environments (pH=5.5, 6.5, 7.5, 8, 9), and measuring cell viability using the CCK-8 assay after culture, PAD-T cells exhibited a certain degree of resistance to external environmental factors, significantly mitigating the effects of acidic (pH≤6.5) and alkaline (pH≥8) conditions on cell viability. *p<0.05, **p<0.01 (±s, n=5).
[0070] Example 9: Enzyme-linked immunosorbent assay (ELISA) to detect cytokine secretion levels in PAD-T cells. PAD-T cells were prepared according to Example 1. Single cells were collected, coated with PAD-T cells, and seeded in 96-well plates (1×10⁻⁶ cells per well) with 10 (V / V)% RPMI medium. 5Cells were cultured at 37°C in a 5 (v / v)% CO2 incubator, and supernatant samples were collected at 24h and 72h. Samples and standards (100µL / well) were added to antibody-coated ELISA sandwich wells, followed by biotinylated antibody working solution (50µL / well). The mixture was thoroughly mixed using a micro-shaker, and the wells were sealed with sealing tape and incubated at room temperature for 120min. 350µL of washing buffer was added to each well, and the plate was allowed to stand for 30s before being shaken dry. The plate was washed four times. Enzyme conjugation working solution (100µL / well) was added, and the plate was sealed and incubated at room temperature for 30min. After washing four times, 100µL of chromogenic reagent was added to each well, and the plate was incubated at room temperature in the dark for 10-20min. 100µL of stop solution was added to each well, and the OD value at 450nm was measured immediately after mixing. Conventional uncoated T cells were used as a control.
[0071] See results Figure 8 Enzyme-linked immunosorbent assay (ELISA) showed that PAD-T coating did not affect the secretion levels of TNF-α (Figure A), IL-2 (Figure B) and IFN-γ (Figure C) within 72 hours after ConA stimulation (±s, n=5).
[0072] Example 10: Flow cytometry detection of PAD-T cell-targeted killing of AML cells PAD-T cells were prepared according to Example 1. AML cells (WEHI-3B) or bone marrow cells were resuspended at a concentration of 1×10⁻⁶. 6 Cells / mL were added to Celltrace Far Red cell proliferation tracking reagent and incubated at 37°C for 15 min to stain and label AML cells (WEHI-3B) or bone marrow cells. The cells were then resuspended in 100 µL of 10 (V / V)% RPMI medium. 1×10⁻⁶ cells / mL were then added to the culture medium. 6 PAD-T cells were added to the cell suspension described above and incubated in a 24-well plate at 37°C for 12 hours. The suspended cells were carefully extracted from the wells, incubated with Anti-CD3-PE for 30 min to label the T cells, and after centrifugation and washing, the expression of CD3 and Far Red markers was detected by flow cytometry. Uncoated T cells were used as a control.
[0073] Figure 9 The results showed that PAD-T cells had a significant targeting effect on AML cells (WEHI-3B) compared to uncoated T cells, but no significant targeting effect on bone marrow cells.
[0074] Example 11: Flow cytometry detection of PAD-T killing AML cells using Annexin V-PI apoptosis kit. AML cells (WEHI-3B) or bone marrow cells from the co-culture system of Example 9 were collected, centrifuged and washed, resuspended in 300µL staining buffer, 5-10µL of FITC-Annexin V reagent was added for staining for 10 minutes, then 5µL of PE-PI reagent was added for staining for 10 minutes, centrifuged and washed, and flow cytometry was used to detect apoptosis of AML cells (WEHI-3B) or bone marrow cells.
[0075] Figure 10 The results showed that late-stage apoptotic cells or dead cells were displayed in the upper right corner of the flow cytometry plot. Compared with the uncoated T cell group, the PAD-T cell group had a stronger killing effect on AML cells (WEHI-3B), but did not produce significant killing effect on bone marrow cells.
[0076] Example 12: Flow cytometry detection of PAD-T cell surface activation markers After inducing mouse macrophages by adding 1 µg / mL LPS to RAW264.7 cells, PAD-T cells prepared according to Example 1 were added and co-cultured in 24-well plates for 3 or 6 days. Uncoated T cells served as the control group, with a co-culture ratio of 1:10. T cells were collected, Anti-FITC-CD25 was added and incubated for 30 min, and the expression of CD25 in PAD-T cells was detected by flow cytometry.
[0077] Figure 11 The results showed that after 3 and 6 days of co-culture, CD25 expression was significantly lower in the PAD-T cell group compared with the uncoated T cell group, indicating that coating significantly delayed the activation effect of heterologous antigen presentation on T cells.
[0078] The above embodiments are only used to illustrate the technical solutions of the present invention, and are not intended to limit the present invention. Although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention should be included within the protection scope of the present invention.
Claims
1. A method for preparing PAD-T cells targeting acute myeloid leukemia cells, wherein the PAD-T cells comprise T cells, a capsule encapsulating the T cells, and a DNA aptamer connected to the capsule; Its features are, Includes the following steps: S1. Process the selected qualified T cells into a single-cell suspension; S2. Add polylysine solution to the cell suspension and incubate to allow polylysine to adsorb onto the surface of the T cells, forming a first polylysine layer; S3. Add sodium alginate solution and incubate to allow sodium alginate to coat the outside of the first polylysine layer, forming the first sodium alginate layer; S4. Repeat step S2 to form the second polylysine layer; S5. Add the DNA rolling circle amplification system solution to the cell suspension from step S4, incubate, and obtain the desired PAD-T cells; The DNA rolling circle amplification system solution includes DNA aptamer primer strands, DNA aptamer template strands, ligase, DNA polymerase, and deoxyribonucleoside triphosphates; The DNA aptamer is a long DNA chain containing n S30-T1 DNA aptamer units, where n is 1000-5000, and the sequence of the S30-T1 DNA aptamer unit is shown in SEQ ID No:1; the thickness of the capsule is 400-800 nm, and the diameter of the PAD-T cell is 7.4-8.5 μm.
2. The method for preparing PAD-T cells targeting acute myeloid leukemia cells according to claim 1, characterized in that, The nucleotide sequence of the DNA aptamer primer chain is shown in SEQ ID NO.2, and the nucleotide sequence of the DNA aptamer template chain is shown in SEQ ID NO.
3.
3. The method for preparing PAD-T cells targeting acute myeloid leukemia cells according to claim 1, characterized in that, The single-use volume of the poly-L-lysine solution is 1 mL / 10. 5-7 For each T cell, the single-dose sodium alginate solution is 1 mL / 10. 5-7 For each T cell, the volume ratio of the material solution to the T cell suspension is (0.5-1.5):(0.5-1.5), and the incubation time is 2-60 min.
4. The method for preparing PAD-T cells targeting acute myeloid leukemia cells according to claim 3, characterized in that, The single-use volume of the poly-L-lysine solution is 1 mL / 10. 6 For each T cell, the single-dose sodium alginate solution is 1 mL / 10. 6 The material solution and the T cell suspension were in a 1:1 volume ratio.
5. The method for preparing PAD-T cells targeting acute myeloid leukemia cells according to claim 1, characterized in that, The specific steps for DNA rolling circle amplification are as follows: S51. Mix DNA aptamer primer strands, DNA aptamer template strands, and ligase buffer, and anneal. S52. Add T4 ligase and incubate; S53. Add Φ29 DNA polymerase, deoxyribonucleoside triphosphate, bovine serum albumin, and Φ29 DNA polymerase reaction solution, mix with the cell suspension from step S4, incubate, and obtain the desired PAD-T cells.
6. The method for preparing PAD-T cells targeting acute myeloid leukemia cells according to claim 5, characterized in that, The amount of DNA aptamer template strand added is 0.4-0.8 μM, the amount of DNA aptamer primer strand added is 1.0-1.4 μM, and then 10× ligase buffer is added, and the volume is made up with deionized water; the final reaction volume based on DNA rolling circle amplification is 100 μl.
7. The method for preparing PAD-T cells targeting acute myeloid leukemia cells according to claim 6, characterized in that, The amount of DNA aptamer template strand added was 0.6 μM, the amount of DNA aptamer primer strand added was 1.2 μM, and then 10× ligase buffer was added, and the volume was made up with deionized water; the final reaction volume based on DNA rolling circle amplification was 100 μl.
8. The method for preparing PAD-T cells targeting acute myeloid leukemia cells according to claim 7, wherein the DNA rolling circle amplification reaction is annealed according to the program of 2 min-95℃, 30 min-65℃, 30 min-50℃, 30 min-37℃, 30 min-22℃, and after annealing, T4 ligase is added at a volume of 10 U / μL, and after incubation for 3 h, Φ29 DNA polymerase is added at a volume of 2 U / μL, and deionized water is added to make up the volume to 100 μL; The ratio of the total volume of the rolling circle amplification reaction system to the volume of the cell suspension is 1:5-15.
9. In the method for preparing PAD-T cells targeting acute myeloid leukemia cells according to claim 8, the ratio of the total volume of the rolling circle amplification reaction system to the volume of the cell suspension is 1:9-11.
10. The method for preparing PAD-T cells targeting acute myeloid leukemia cells according to claim 5, characterized in that, The incubation time in step S52 is 3 hours, and the incubation time in step S53 is 1 to 2 hours.
Citation Information
Patent Citations
Alginate-epsilon-polylysine microcapsules and preparation and application thereof
CN102101036A
GA-T cell, preparation method thereof and application thereof in leukemia and GVHD resistance
CN113584012A
Cascade targeting drug for resisting acute myelogenous leukemia and preparation method thereof
CN117797267A
